These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 2878363

  • 1. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
    Stern DF, Heffernan PA, Weinberg RA.
    Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
    [Abstract] [Full Text] [Related]

  • 2. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
    Kokai Y, Dobashi K, Weiner DB, Myers JN, Nowell PC, Greene MI.
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
    [Abstract] [Full Text] [Related]

  • 3. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.
    Connelly PA, Stern DF.
    Proc Natl Acad Sci U S A; 1990 Aug; 87(16):6054-7. PubMed ID: 1974718
    [Abstract] [Full Text] [Related]

  • 4. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.
    Bargmann CI, Weinberg RA.
    Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5394-8. PubMed ID: 2899890
    [Abstract] [Full Text] [Related]

  • 5. EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.
    Stern DF, Kamps MP.
    EMBO J; 1988 Apr; 7(4):995-1001. PubMed ID: 3261240
    [Abstract] [Full Text] [Related]

  • 6. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
    Lehväslaiho H, Lehtola L, Sistonen L, Alitalo K.
    EMBO J; 1989 Jan; 8(1):159-66. PubMed ID: 2565807
    [Abstract] [Full Text] [Related]

  • 7. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
    Guy PM, Carraway KL, Cerione RA.
    J Biol Chem; 1992 Jul 15; 267(20):13851-6. PubMed ID: 1352772
    [Abstract] [Full Text] [Related]

  • 8. Stage- and tissue-specific expression of the neu oncogene in rat development.
    Kokai Y, Cohen JA, Drebin JA, Greene MI.
    Proc Natl Acad Sci U S A; 1987 Dec 15; 84(23):8498-501. PubMed ID: 3317411
    [Abstract] [Full Text] [Related]

  • 9. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
    Ben-Levy R, Peles E, Goldman-Michael R, Yarden Y.
    J Biol Chem; 1992 Aug 25; 267(24):17304-13. PubMed ID: 1355090
    [Abstract] [Full Text] [Related]

  • 10. Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase.
    Sistonen L, Hölttä E, Lehväslaiho H, Lehtola L, Alitalo K.
    J Cell Biol; 1989 Nov 25; 109(5):1911-9. PubMed ID: 2572601
    [Abstract] [Full Text] [Related]

  • 11. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
    Stern DF, Kamps MP, Cao H.
    Mol Cell Biol; 1988 Sep 25; 8(9):3969-73. PubMed ID: 2464744
    [Abstract] [Full Text] [Related]

  • 12. An extra cysteine proximal to the transmembrane domain induces differential cross-linking of p185neu and p185neu.
    Cao H, Bangalore L, Dompé C, Bormann BJ, Stern DF.
    J Biol Chem; 1992 Oct 05; 267(28):20489-92. PubMed ID: 1356980
    [Abstract] [Full Text] [Related]

  • 13. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
    Volm M, Kästel M, Mattern J, Efferth T.
    Cancer; 1993 Jun 15; 71(12):3981-7. PubMed ID: 8099529
    [Abstract] [Full Text] [Related]

  • 14. Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene.
    Lev S, Yarden Y, Givol D.
    Mol Cell Biol; 1990 Nov 15; 10(11):6064-8. PubMed ID: 1700279
    [Abstract] [Full Text] [Related]

  • 15. Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat neu oncogene.
    Reardon DB, Hung MC.
    J Biol Chem; 1993 Aug 25; 268(24):18136-42. PubMed ID: 7688739
    [Abstract] [Full Text] [Related]

  • 16. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.
    Cao H, Decker S, Stern DF.
    Oncogene; 1991 May 25; 6(5):705-11. PubMed ID: 1675782
    [Abstract] [Full Text] [Related]

  • 17. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
    Lehtola L, Sistonen L, Koskinen P, Lehväslaiho H, Di Renzo MF, Comoglio PM, Alitalo K.
    J Cell Biochem; 1991 Jan 25; 45(1):69-81. PubMed ID: 1706346
    [Abstract] [Full Text] [Related]

  • 18. Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes.
    Qian X, O'Rourke DM, Fei Z, Zhang HT, Kao CC, Greene MI.
    J Biol Chem; 1999 Jan 08; 274(2):574-83. PubMed ID: 9872991
    [Abstract] [Full Text] [Related]

  • 19. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation.
    Samanta A, LeVea CM, Dougall WC, Qian X, Greene MI.
    Proc Natl Acad Sci U S A; 1994 Mar 01; 91(5):1711-5. PubMed ID: 7907421
    [Abstract] [Full Text] [Related]

  • 20. Differential processing and turnover of the oncogenically activated neu/erb B2 gene product and its normal cellular counterpart.
    Huang SS, Koh HA, Konish Y, Bullock LD, Huang JS.
    J Biol Chem; 1990 Feb 25; 265(6):3340-6. PubMed ID: 1968062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.